Ryman Healthcare (NZSE:RYM) Half Year Loss Narrows Challenging Bearish Turnaround Doubts

Simply Wall St.

May 27

Ryman Healthcare (NZSE:RYM) has reported its FY 2026 first half with revenue of NZ$413.5 million and a basic EPS loss of NZ$0.04, while trailing 12 month figures show revenue of NZ$855.6 million and a...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2638894576"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2638894576\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2638894576?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6033000-choice2-main-header/1585186569462","is_english":true,"pubTime":"2026-05-27 19:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2638894576","market":"hk","top_or_hot":-1,"title":"Ryman Healthcare (NZSE:RYM) Half Year Loss Narrows Challenging Bearish Turnaround Doubts","media":"Simply Wall St.","content":"<div>\n<p>Ryman Healthcare (NZSE:RYM) has reported its FY 2026 first half with revenue of NZ$413.5 million and a basic EPS loss of NZ$0.04, while trailing 12 month figures show revenue of NZ$855.6 million and a...</p>\n\n<a href=\"https://simplywall.st/stocks/nz/healthcare/nzx-rym/ryman-healthcare-shares/news/ryman-healthcare-nzserym-half-year-loss-narrows-challenging\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ryman Healthcare (NZSE:RYM) Half Year Loss Narrows Challenging Bearish Turnaround Doubts</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRyman Healthcare (NZSE:RYM) Half Year Loss Narrows Challenging Bearish Turnaround Doubts\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-27 19:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/nz/healthcare/nzx-rym/ryman-healthcare-shares/news/ryman-healthcare-nzserym-half-year-loss-narrows-challenging><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ryman Healthcare (NZSE:RYM) has reported its FY 2026 first half with revenue of NZ$413.5 million and a basic EPS loss of NZ$0.04, while trailing 12 month figures show revenue of NZ$855.6 million and a...</p>\n\n<a href=\"https://simplywall.st/stocks/nz/healthcare/nzx-rym/ryman-healthcare-shares/news/ryman-healthcare-nzserym-half-year-loss-narrows-challenging\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4152","symbol_name":"农用农业机械","start_time":0,"source_url":"https://simplywall.st/stocks/nz/healthcare/nzx-rym/ryman-healthcare-shares/news/ryman-healthcare-nzserym-half-year-loss-narrows-challenging","article_id":"2638894576","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6033000-choice2-main-header/1585186569462"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/nz/healthcare/nzx-rym/ryman-healthcare-shares/news/ryman-healthcare-nzserym-half-year-loss-narrows-challenging","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2638894576","pubTimestamp":1779880191,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Ryman Healthcare (NZSE:RYM) has reported its FY 2026 first half with revenue of NZ$413.5 million and a basic EPS loss of NZ$0.04, while trailing 12 month figures show revenue of NZ$855.6 million and a basic EPS loss of NZ$0.17 as the company works through a period of weaker profitability. The company has seen revenue move from NZ$365.2 million in the first half of FY 2025 to NZ$394.0 million in the second half and now NZ$413.5 million in the first half of FY 2026, with EPS swinging from a...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4152":"农用农业机械","XBI":"SPDR S&P Biotech ETF","LABU":"三倍做多标普生物-Direxion","BK8050":"保健护理机构","XLV":"健康照护类股ETF-SPDR","BK4581":"高盛持仓","BK4588":"碎股","BK4585":"ETF&股票定投概念","RYM.NZ":"Ryman Healthcare Limited Ordinary Shares","RYM":"RYTHM Inc."},"translate_title":"Ryman Healthcare(NZSE：RYM)半年亏损收窄，挑战看跌扭亏为盈疑虑","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RYM":1.5,"XLV":1.5,"XBI":0.6,"LABU":0.6,"RYM.NZ":1.5},"content_text":"Ryman Healthcare (NZSE:RYM) has reported its FY 2026 first half with revenue of NZ$413.5 million and a basic EPS loss of NZ$0.04, while trailing 12 month figures show revenue of NZ$855.6 million and a basic EPS loss of NZ$0.17 as the company works through a period of weaker profitability. The company has seen revenue move from NZ$365.2 million in the first half of FY 2025 to NZ$394.0 million in the second half and now NZ$413.5 million in the first half of FY 2026, with EPS swinging from a profit of NZ$0.12 to a loss of NZ$0.72 and then a smaller loss of NZ$0.04. Overall, the latest numbers point to pressure on margins, and investors may focus on whether the current revenue base is sufficient to support a more stable earnings profile. See our full analysis for Ryman Healthcare. With the headline figures reported, the next step is to consider how these results align with the widely followed growth and risk narratives around Ryman Healthcare and whether those narratives may need to be revisited. See what the community is saying about Ryman Healthcare NZSE:RYM Earnings & Revenue History as at May 2026 AdvertisementTTM loss of NZ$171.3m keeps profitability in focus  On a trailing 12 month basis, Ryman reported total revenue of NZ$855.6 million and a net loss of NZ$171.3 million, compared with a NZ$45.2 million loss in the latest half year. Bulls argue that new leadership and an operational reset can shift these losses into strong profits, yet the current loss profile and unprofitable trailing 12 month record sit in clear tension with that view.\n     The bullish narrative looks for earnings of NZ$624.8 million to NZ$776.4 million by around 2029, which is a very large swing from the latest trailing 12 month loss of NZ$171.3 million. Cost savings of NZ$18 million per year and higher pricing are part of the bullish case, but the recent half year still shows a loss of NZ$45.2 million, so the turnaround is not yet visible in the reported earnings.    Bulls who see this as an early inflection point can compare the current loss profile with the full optimistic thesis in the 🐂 Ryman Healthcare Bull Case. Losses and debt weigh on the bearish case  Over the past five years, losses have grown at about 63.7% per year and the company ended the trailing 12 month period with a net loss of NZ$171.3 million, while carrying NZ$2.56b of debt according to the risk summary. Bears highlight that this loss trend, together with high leverage and interest costs that are not well covered by earnings, could limit flexibility even if revenue is forecast to grow by 5.7% per year.\n     Interest payments are flagged as a major financial risk because current earnings do not comfortably cover them, which aligns with the trailing 12 month loss and the NZ$2.56b debt figure. Concerns about housing cycles and regulatory pressure in New Zealand and Australia are layered on top of this balance sheet position, which bears see as a risk to cash flow consistency, even though the latest half year loss of NZ$45.2 million is smaller than the trailing 12 month loss.    If you are weighing these risks carefully, you may want to see how skeptics frame the downside in the 🐻 Ryman Healthcare Bear Case. Valuation gap between NZ$2.30 price and DCF fair value  The stock trades at NZ$2.30 per share against a DCF fair value of NZ$0.82 and a P/S ratio of 2.7x, compared with 2.1x for peers and 1.0x for the wider Oceanic Healthcare industry. Consensus narrative suggests that a price target of NZ$3.06 is supported by forecasts for 6.6% annual revenue growth and a move from heavy losses toward NZ$624.8 million in earnings by around 2029. However, the current premium to DCF fair value and richer P/S multiples show that the market is already paying up for that outlook.\n     The gap between the NZ$2.30 share price and the NZ$0.82 DCF fair value implies a meaningful valuation premium while the business is still loss making on a trailing 12 month basis. At the same time, the consensus price target of NZ$3.06 sits above the current price, which reflects expectations for stronger margins and earnings than those seen in the latest reported net loss of NZ$171.3 million.    Next Steps To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Ryman Healthcare on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves. If this mix of risks and potential rewards feels finely balanced, act while the details are fresh and test the numbers for yourself with 2 key rewards and 2 important warning signs See What Else Is Out There Ryman Healthcare is working through sizeable losses, a heavy NZ$2.56b debt load and interest costs that current earnings do not comfortably cover. If that mix of losses and leverage feels uncomfortable, you can quickly refocus on companies with stronger balance sheets and steadier fundamentals by checking the solid balance sheet and fundamentals stocks screener (394 results).  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}